Association between morning symptoms and physical activity in COPD: A systematic review

European Respiratory Review

Volumn 26, Issue 143, 2017, Pages

  Van Buul, Amanda R ^a   Kasteleyn, Marise J ^a   Chavannes, Niels H ^a   Taube, Christian ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY; AROUSAL; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COPING BEHAVIOR; COUGHING; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; HUMAN; MEDICATION COMPLIANCE; PHYSICAL ACTIVITY; REVIEW; SEDENTARY LIFESTYLE; SLEEP DISORDER; SLEEP QUALITY; SPUTUM; SYSTEMATIC REVIEW; TASK PERFORMANCE; WALKING SPEED; WHEEZING; ADULT; AGED; CIRCADIAN RHYTHM; DISEASE EXACERBATION; DRUG EFFECTS; EXERCISE; EXERCISE TOLERANCE; FEMALE; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; AGED; CIRCADIAN RHYTHM; DISEASE PROGRESSION; EXERCISE; EXERCISE TOLERANCE; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEDENTARY LIFESTYLE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85008655968     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0033-2016     Document Type: Review

References (42)

1. Murray CJ, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet 2013; 381: 997-1020.
2. WHO. Top ten causes of death. www.who.int/mediacentre/factsheets/fs310/en/ Date last updated: May 2014. Date last accessed: March 14, 2016.
3. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014; 44: 1521-1537.
4. Global Strategy for the Diagnosis MaPoC. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org/. Date last updated: Dec 2015. Date last accessed: March 14, 2016.
5. Tsiligianni I, Kocks J, Tzanakis N, et al. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J 2011; 20: 257-268.
6. Katajisto M, Kupiainen H, Rantanen P, et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int J Chron Obstruct Pulmon Dis 2012; 7: 743-755.
7. Kulich K, Keininger DL, Tiplady B, et al. Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study. Int J Chron Obstruct Pulmon Dis 2015; 10: 79-94.
8. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res 2013; 14: 112.
9. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
10. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4: e296.
11. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-662.
12. Poorolajal J, Cheraghi Z, Irani AD, et al. Quality of cohort studies reporting post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Epidemiol Health 2011; 33: e2011005.
13. Altmann VC, Hart AL, Vanlandewijck YC, et al. The impact of trunk impairment on performance of wheelchair activities with a focus on wheelchair court sports: a systematic review. Sports Med Open 2015; 1: 6.
14. Ramesh A, Blanchet K, Ensink JH, et al. Evidence on the effectiveness of water, sanitation, and hygiene (WASH) interventions on health outcomes in humanitarian crises: a systematic review. PLoS One 2015; 10: e0124688.
15. Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res 2015; 16: 92.
16. Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res 2014; 15: 122.
17. Roche N, Small M, Broomfield S, et al. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD 2013; 10: 679-686.
18. Kim YJ, Lee BK, Jung CY, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med 2012; 27: 426-435.
19. O’Hagan P, Chavannes NH. The impact of morning symptoms on daily activities in chronic obstructive pulmonary disease. Curr Med Res Opin 2014; 30: 301-314.
20. Stephenson JJ, Cai Q, Mocarski M, et al. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 577-586.
21. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-2048.
22. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37: 264-272.
23. Partridge MR, Miravitlles M, Stahl E, et al. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 2010; 36: 96-104.
24. Palsgrove A, Houghton K, Hareendran A, et al. The development of the early morning symptoms of COPD instrument (EMSCI). Value Health 2011; 14: A496-A497.
25. Garrow AP, Khan N, Tyson S, et al. The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. Thorax 2015; 70: 757-763.
26. Waschki B, Kirsten AM, Holz O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 295-306.
27. Miravitlles M, Ferrer J, Baro E, et al. Differences between physician and patient in the perception of symptoms and their severity in COPD. Respir Med 2013; 107: 1977-1985.
28. Bjorner JB, Rose M, Gandek B Jr., et al. Difference in method of administration did not significantly impact item response: an IRT-based analysis from the Patient-Reported Outcomes Measurement Information System (PROMIS) initiative. Qual Life Res 2014; 23: 217-227.
29. Muehlhausen W, Doll H, Quadri N, et al. Equivalence of electronic and paper administration of patient-reported outcome measures: a systematic review and meta-analysis of studies conducted between 2007 and 2013. Health Qual Life Outcomes 2015; 13: 167.
30. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972-977.
31. Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 2010; 104: 1005-1011.
32. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
33. Brawner CA, Churilla JR, Keteyian SJ. Prevalence of physical activity is lower among individuals with chronic disease. Med Sci Sports Exerc 2016.
34. Watz H, Waschki B, Meyer T, et al. Physical activity in patients with COPD. Eur Respir J 2009; 33: 262-272.
35. Wick K, Faude O, Schwager S, et al. Deviation between self-reported and measured occupational physical activity levels in office employees: effects of age and body composition. Int Arch Occup Environ Health 2016; 89: 575-82.
36. Rabinovich RA, Louvaris Z, Raste Y, et al. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J 2013; 42: 1205-1215.
37. Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med 2015; 109: 616-624.
38. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/ formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1-11.
39. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
40. Clark TJ. Diurnal rhythm of asthma. Chest 1987; 91: 137S-141S.
41. Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis 2013; 8: 231-238.
42. Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011; 20: 183-194.